2015 Conference on Retroviruses and Opportunistic Infections*

February 23-26, 2015; Seattle, Washington
Review Capsule Summaries, a slideset, and a module containing expert faculty analysis on the most clinically relevant studies from the Seattle meeting.

Highlights From Seattle 2015


Similar low rates of virologic failure and safety endpoints seen in both arms.

Released: February 28, 2015

Inflammatory marker levels at baseline associated with increases in peripheral fat and lean body mass, but not central adiposity.

Released: March 2, 2015

Over 5 years of exposure, the risk of developing CKD increased > 300-fold with atazanavir/ritonavir, > 200-fold with lopinavir/ritonavir, and 174-fold with tenofovir DF compared with no exposure to each agent.

Released: March 2, 2015

Improved safety profile likely attributable to 90% lower plasma tenofovir levels in patients receiving EVG/COBI/FTC/TAF vs EVG/COBI/FTC/TDF.

Released: March 2, 2015

In multivariate analysis, no impact of previous treatment experience, cirrhosis status or ARV regimen on SVR; all 10 patients with relapse were black.

Released: February 28, 2015

Good adherence to event-driven dosing regimen delivered before and after sex without evidence of risk compensation

Released: February 26, 2015

Treatment-naive patients who received oral cabotegravir-based induction and maintenance therapy experienced numerically lower rates of discontinuation for AEs and had comparable virologic suppression rates compared with patients treated with efavirenz-based therapy through 96 weeks.

Released: February 28, 2015

The increased risk of MI identified in individuals who received abacavir was diminished after adjusting for cardiovascular and HIV-associated risk factors.

Released: February 28, 2015
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?